Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Treasury Shares (2020 - 2024)

Historic Treasury Shares for Relay Therapeutics (RLAY) over the last 5 years, with Q4 2024 value amounting to $5.8 million.

  • Relay Therapeutics' Treasury Shares rose 9412.36% to $5.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.8 million, marking a year-over-year increase of 9412.36%. This contributed to the annual value of $5.8 million for FY2024, which is 9412.36% up from last year.
  • Relay Therapeutics' Treasury Shares amounted to $5.8 million in Q4 2024, which was up 9412.36% from $3.0 million recorded in Q4 2023.
  • Relay Therapeutics' 5-year Treasury Shares high stood at $5.8 million for Q4 2024, and its period low was $84489.0 during Q4 2020.
  • Its 5-year average for Treasury Shares is $1.7 million, with a median of $691205.0 in 2021.
  • Its Treasury Shares has fluctuated over the past 5 years, first surged by 71810.06% in 2021, then skyrocketed by 9098.31% in 2023.
  • Relay Therapeutics' Treasury Shares (Quarter) stood at $84489.0 in 2020, then surged by 718.1% to $691205.0 in 2021, then soared by 126.67% to $1.6 million in 2022, then skyrocketed by 90.98% to $3.0 million in 2023, then skyrocketed by 94.12% to $5.8 million in 2024.
  • Its Treasury Shares stands at $5.8 million for Q4 2024, versus $3.0 million for Q4 2023 and $1.6 million for Q4 2022.